Wachtell Guides Pfizer’s $5.2B Anacor Deal

Law360, New York (May 16, 2016, 11:58 AM EDT) -- Pfizer, led by Wachtell Lipton Rosen & Katz, unveiled a $5.2 billion cash deal for dermatological treatment developer Anacor on Monday, marking the U.S. pharmaceutical giant’s first major deal since scrapping a record inversion deal with Irish drugmaker Allergan.

Pfizer Inc. said it will pay $99.25 per share in cash to acquire Anacor Pharmaceuticals Inc., whose flagship product is under review by the U.S. Food and Drug Administration for the treatment of mild to moderate atopic dermatitis, or eczema, according to a statement.

The goal date...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.